A new look at benefits of drug therapy in silent myocardial ischaemia
Author:
Open Access
- 19 July 2007
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 28 (17) , 2053-2054
Abstract
Over 25 years ago we prepared a classification system for silent myocardial ischaemia that we hoped would make it easier for future researchers to study the pathophysiogical basis for the syndrome, establish prognosis, and determine appropriate management protocols.1 In our categorization, Cohn Type I refers to asymptomatic individuals without known coronary artery disease (CAD) and Cohn Types II and III to patients with known CAD. Those with prior myocardial infarctions (MIs) who are asymptomatic are Type II, and those with CAD and both silent and symptomatic ischaemic episodes are Type III.1 In the last decade a dedicated group of Swiss cardiologists led by Dr Mathias Pfister of the Basel University Hospital have conducted a long-term series of clinical studies involving patients with Types I and II silent ischaemia. By providing a ‘new look’ at the syndrome of silent ischaemia they have contributed important clinical data to aid in its management. They have now described the results of anti-ischaemia drug therapy in Type I patients (studied in their SWISS I trial);2 their SWISS II data dealing with Type 2 patients and also recently published3 will be commented on later in this editorial.Keywords
This publication has 6 references indexed in Scilit:
- Effects of anti-ischaemic drug therapy in silent myocardial ischaemia type I: the Swiss Interventional Study on Silent Ischaemia type I (SWISSI I): a randomized, controlled pilot studyEuropean Heart Journal, 2007
- Effects of Percutaneous Coronary Interventions in Silent Ischemia After Myocardial InfarctionJAMA, 2007
- Detection of Coronary Artery Disease in Asymptomatic Patients With Type 2 Diabetes MellitusJACC, 2006
- Prevalence and prognostic significance of daily-life silent myocardial ischaemia in middle-aged and elderly subjects with no apparent heart diseaseEuropean Heart Journal, 2005
- Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life. The Atenolol Silent Ischemia Study (ASIST)Circulation, 1994
- Initial clinical presentation of cardiac disease in asymptomatic men with silent myocardial ischemia and angiographically documented coronary artery disease (the Oslo Ischemia Study)The American Journal of Cardiology, 1993